SCHEMBL1157582

SCHEMBL1157582

COc1c(N)cccc1OCC1CC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.45
MCHR1 Q99705 3/20 0.43
HTR2C P28335 3/20 0.41
TDP1 Q9NUW8 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
ADRA2B P18089 1/20 0.40
PTGS1 P23219 1/20 0.40
DHFR P00374 1/20 0.39
DCPS Q96C86 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
BRD4 O60885 2/20 0.38
CREBBP Q92793 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16011771 0.87 SMN1; SMN2 (0.44) RIPK1MCHR1HTR2CTDP1ALDH1A1
SCHEMBL16011779 0.81 MCHR1 (0.48) MCHR1TDP1ALDH1A1CHRNB4CHRNA3
SCHEMBL28474252 0.80 RIPK1 (0.47) RIPK1MCHR1HTR2CALDH1A1DHFR
SCHEMBL10503371 0.80 MCHR1 (0.48) RIPK1MCHR1HTR2CALDH1A1DHFR
SCHEMBL23493020 0.79 ALDH1A1 (0.53) RIPK1MCHR1HTR2CTDP1ALDH1A1
SCHEMBL3798519 0.79 ALDH1A1 (0.53) RIPK1MCHR1HTR2CTDP1ALDH1A1
SCHEMBL28324547 0.78 PARP15 (0.50) RIPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL3426858 0.78 ALDH1A1 (0.62) TDP1ALDH1A1ADRA2BPTGS1PDE4A
SCHEMBL2587027 0.78 SMN1; SMN2 (0.57) RIPK1ALDH1A1CHRNB4CHRNA3PDE4A
SCHEMBL21694298 0.76 RIPK1 (0.48) RIPK1MCHR1HTR2CTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046146-A9 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2011-02-24 US disclosed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
US-7205320-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-17 US disclosed
US-20070078139-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2007-04-05 US disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US disclosed
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 US disclosed
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 US disclosed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US disclosed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149052-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A RIPK1 4381/4885MCHR1 2622/4885HTR2C 738/4885
US-20020151566-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A RIPK1 4381/4885MCHR1 2622/4885HTR2C 738/4885
US-20040230072-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A RIPK1 4381/4885MCHR1 2622/4885HTR2C 738/4885
US-20110046146-A9 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B RIPK1 4590/4885MCHR1 2474/4885HTR2C 875/4885
US-20070078139-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B RIPK1 4590/4885MCHR1 2474/4885HTR2C 875/4885
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A RIPK1 4699/4885MCHR1 2564/4885HTR2C 653/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A RIPK1 4699/4885MCHR1 2564/4885HTR2C 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.